Ge Long Hui·2026-01-09 09:53Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Bromides of the oral solution, which is used to treat myasthenia gravis, marking a significant milestone for the company in expanding its product portfolio in the pharmaceutical market [1] Group 1: Product Approval - The oral solution of Bromides has been granted a drug registration certificate (Certificate No: 2025S04074) by the National Medical Products Administration [1] - The product was originally developed by BAUSCH and was first launched in the United States in 1965 [1] - Shanghai Pharmaceuticals submitted the registration application for this product in April 2024, which has been accepted by the regulatory authority [1] Group 2: Financial Investment - The company has invested approximately RMB 2.3174 million in research and development for this product as of the date of the announcement [1] - There are currently no other companies in China that have this product listed for sale [1] Group 3: Market Potential - According to the IQVIA database, the procurement amount for Bromides tablets in hospitals in mainland China is RMB 60.29 million for the year 2024 [1]